A role for quercetin in coronavirus disease 2019 (COVID-19)

Derosa et al., Phytotherapy Research, doi:10.1002/ptr.6887, Oct 2020

Source

PDF

All
Studies

Meta
Analysis

https://c19early.org/derosa2.html

Quercetin for COVID-19

26th treatment shown to reduce risk in July 2021, now with p = 0.002 from 12 studies.

Lower risk for ICU, hospitalization, recovery, cases, and viral clearance.

No treatment is 100% effective. Protocols combine treatments.

5,700+ studies for 135 treatments. c19early.org

Review noting that quercetin has a theoretical, but significant, capability to interfere with SARS-CoV-2 replication, with results showing this to be the fifth best compound out of 18 candidates.

Reviews covering quercetin for COVID-19 include1-20.

Important missing comments or errors? Let us know.

1. Sanduzzi Zamparelli et al., Immune-Boosting and Antiviral Effects of Antioxidants in COVID-19 Pneumonia: A Therapeutic Perspective, Life, doi:10.3390/life15010113.mdpi.com, doi.org.

2. Duan et al., Bioactive compounds,quercetin, curcumin and β-glucan,regulate innate immunity via the gut-liver-brain axis, Trends in Food Science & Technology, doi:10.1016/j.tifs.2024.104864.sciencedirect.com, doi.org.

3. Beşler et al., Investigation of potential effects of quercetin on COVID-19 treatment: a systematic review of randomized controlled trials, Clinical Science of Nutrition, doi:10.62210/ClinSciNutr.2024.86.clinscinutr.org, doi.org.

4. Ho et al., Therapeutic Implications of Quercetin and its Derived-products in COVID-19 Protection and Prophylactic, Heliyon, doi:10.1016/j.heliyon.2024.e30080.sciencedirect.com, doi.org.

5. Vajdi et al., Effect of polyphenols against complications of COVID-19: current evidence and potential efficacy, Pharmacological Reports, doi:10.1007/s43440-024-00585-6.springer.com, doi.org.

6. Chen et al., Effect and mechanism of quercetin or quercetin‐containing formulas against COVID‐19: From bench to bedside, Phytotherapy Research, doi:10.1002/ptr.8175.wiley.com, doi.org.

7. Yong et al., Natural Products-Based Inhaled Formulations for Treating Pulmonary Diseases, International Journal of Nanomedicine, doi:10.2147/ijn.s451206.dovepress.com, doi.org.

8. Agrawal et al., Antiviral Significance of Isoquercetin (Quercetin-3-O-Glucoside) With Special Reference to its Anti-Coronaviral Potential, Natural Product Communications, doi:10.1177/1934578X231219560.sagepub.com, doi.org.

9. Matías-Pérez et al., Relationship of quercetin intake and oxidative stress in persistent Covid, Frontiers in Nutrition, doi:10.3389/fnut.2023.1278039.frontiersin.org, doi.org.

10. Georgiou et al., Quercetin: A Potential Polydynamic Drug, Molecules, doi:10.3390/molecules28248141.mdpi.com, doi.org.

11. Donzelli, A., Neglected Effective Early Therapies against COVID-19: Focus on Functional Foods and Related Active Substances. A Review, MDPI AG, doi:10.20944/preprints202312.1178.v1.preprints.org, doi.org.

12. Dinda et al., Anti-SARS-CoV-2, antioxidant and immunomodulatory potential of dietary flavonol quercetin: Focus on molecular targets and clinical efficacy, European Journal of Medicinal Chemistry Reports, doi:10.1016/j.ejmcr.2023.100125.sciencedirect.com, doi.org.

13. Mirza et al., Quercetin as a Therapeutic Product: Evaluation of Its Pharmacological Action and Clinical Applications—A Review, Pharmaceuticals, doi:10.3390/ph16111631.mdpi.com, doi.org.

14. Massimo Magro et al., Use of Quercetin for Therapeutic Purposes in COVID-19 Infections: The Opinion of the Geriatrician Doctor, Journal of Modern Biology and Drug Discovery, doi:10.53964/jmbdd.2023004.innovationforever.com, doi.org.

15. Shorobi et al., Quercetin: A Functional Food-Flavonoid Incredibly Attenuates Emerging and Re-Emerging Viral Infections through Immunomodulatory Actions, Molecules, doi:10.3390/molecules28030938.mdpi.com, doi.org.

16. Gasmi et al., Quercetin in the Prevention and Treatment of Coronavirus Infections: A Focus on SARS-CoV-2, Pharmaceuticals, doi:10.3390/ph15091049.mdpi.com, doi.org.

17. Rizky et al., The pharmacological mechanism of quercetin as adjuvant therapy of COVID-19, Life Research, doi:10.53388/life2022-0205-302.tmrjournals.com, doi.org.

18. Imran et al., The Therapeutic and Prophylactic Potential of Quercetin against COVID-19: An Outlook on the Clinical Studies, Inventive Compositions, and Patent Literature, Antioxidants, doi:10.3390/antiox11050876.mdpi.com, doi.org.

19. Derosa et al., A role for quercetin in coronavirus disease 2019 (COVID-19), Phytotherapy Research, doi:10.1002/ptr.6887.wiley.com, doi.org.

20. Biancatelli et al., Quercetin and Vitamin C: An Experimental, Synergistic Therapy for the Prevention and Treatment of SARS-CoV-2 Related Disease (COVID-19), Frontiers in Immunology, doi:10.3389/fimmu.2020.01451.frontiersin.org, doi.org.

Derosa et al., 9 Oct 2020, peer-reviewed, 4 authors.

This Paper Quercetin All

Abstract: Received: 24 May 2020 Revised: 5 September 2020 Accepted: 13 September 2020 DOI: 10.1002/ptr.6887 REVIEW A role for quercetin in coronavirus disease 2019 (COVID-19) Giuseppe Derosa1,2 | Pamela Maffioli1 | 1 Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy 2 Laboratory of Molecular Medicine, University of Pavia, Pavia, Italy 3 Velleja Research S.r.l., Milan, Italy Correspondence Giuseppe Derosa, Department of Internal Medicine and Therapeutics, University of Pavia, Via Aselli, 43/45, 27100 Pavia, Italy. Email: giuseppe.derosa@unipv.it Angela D'Angelo2 | Francesco Di Pierro3 Several months ago, an outbreak of pneumonia of unknown aetiology was detected in Wuhan City (China) and the aetiological agent of the atypical pneumonia was isolated by the Chinese authorities as novel coronavirus (2019-nCoV or SARS-CoV-2). The WHO announced this new disease was to be known as “COVID-19.” When looking for new antiviral compounds, knowledge of the main viral proteins is fundamental. The major druggable targets of SARS-CoV-2 include 3-chymotrypsin-like protease (3CLpro), papain-like protease (PLpro), RNA-dependent RNA polymerase, and spike (S) protein. Quercetin inhibits 3CLpro and PLpro with a docking binding energy corresponding to −6.25 and −4.62 kcal/mol, respectively. Quercetin has a theoretical, but significant, capability to interfere with SARS-CoV-2 replication, with the results showing this to be the fifth best compound out of 18 candidates. On the basis of the clinical COVID-19 manifestations, the multifaceted aspect of quercetin as both antiinflammatory and thrombin-inhibitory actions, should be taken into consideration. KEYWORDS COVID-19, infectious diseases, nutraceutical, quercetin, SARS-CoV-2 1 | I N T RO DU CT I O N appeared in Europe. The virus was isolated in Bavaria (Germany) from a German patient infected by an individual from Shanghai (China). Viral diseases continue to pose a serious threat to public health. The Subsequently, the virus was present in Italy on January 25, 2020. The world has witnessed several viral epidemics over the past 20 years, unsuspecting individuals infected with the virus are thought to have including severe acute respiratory syndrome (SARS) coronavirus been able to circulate in the area of Basso Lodigiano with few symp- (SARS-CoV-1) in 2003, the influenza disease called H1N1 in 2009, toms or with symptoms mistaken for those of influenza. and the middle east respiratory syndrome (MERS) coronavirus (MERS- On January 30, 2020, the WHO declared the situation a public CoV) in 2012. Several months ago, an outbreak of pneumonia of health unknown aetiology was detected in Wuhan City, Province of Hubei Organization, 2020a) and on February 11, 2020, the WHO announced emergency of international concern (World Health (China) and reported to the China Country Office of the World Health that the disease caused by this new virus was to be known as Organization (WHO) on December 31, 2019. The National Health “COVID-19,” which is an acronym of “coronavirus disease-2019.” Commission of China reported the outbreak was associated with On February 20, 2020, the first symptomatic COVID-19 patient exposure in one seafood market in Wuhan City. The aetiological agent was identified in Italy at the Emergency Department of Codogno Hos- of the atypical pneumonia was isolated on January 7, 2020 by the pital, Basso Lodigiano, Province of..

DOI record: { "DOI": "10.1002/ptr.6887", "ISSN": [ "0951-418X", "1099-1573" ], "URL": "http://dx.doi.org/10.1002/ptr.6887", "abstract": "Several months ago, an outbreak of pneumonia of unknown aetiology was detected in Wuhan City (China) and the aetiological agent of the atypical pneumonia was isolated by the Chinese authorities as novel coronavirus (2019‐nCoV or SARS‐CoV‐2). The WHO announced this new disease was to be known as “COVID‐19.” When looking for new antiviral compounds, knowledge of the main viral proteins is fundamental. The major druggable targets of SARS‐CoV‐2 include 3‐chymotrypsin‐like protease (3CLpro), papain‐like protease (PLpro), RNA‐dependent RNA polymerase, and spike (S) protein. Quercetin inhibits 3CLpro and PLpro with a docking binding energy corresponding to −6.25 and −4.62 kcal/mol, respectively. Quercetin has a theoretical, but significant, capability to interfere with SARS‐CoV‐2 replication, with the results showing this to be the fifth best compound out of 18 candidates. On the basis of the clinical COVID‐19 manifestations, the multifaceted aspect of quercetin as both antiinflammatory and thrombin‐inhibitory actions, should be taken into consideration.", "alternative-id": [ "10.1002/ptr.6887" ], "assertion": [ { "group": { "label": "Publication History", "name": "publication_history" }, "label": "Received", "name": "received", "order": 0, "value": "2020-05-24" }, { "group": { "label": "Publication History", "name": "publication_history" }, "label": "Accepted", "name": "accepted", "order": 1, "value": "2020-09-13" }, { "group": { "label": "Publication History", "name": "publication_history" }, "label": "Published", "name": "published", "order": 2, "value": "2020-10-09" } ], "author": [ { "ORCID": "http://orcid.org/0000-0003-3573-4760", "affiliation": [ { "name": "Department of Internal Medicine and Therapeutics University of Pavia Pavia Italy" }, { "name": "Laboratory of Molecular Medicine University of Pavia Pavia Italy" } ], "authenticated-orcid": false, "family": "Derosa", "given": "Giuseppe", "sequence": "first" }, { "affiliation": [ { "name": "Department of Internal Medicine and Therapeutics University of Pavia Pavia Italy" } ], "family": "Maffioli", "given": "Pamela", "sequence": "additional" }, { "affiliation": [ { "name": "Laboratory of Molecular Medicine University of Pavia Pavia Italy" } ], "family": "D'Angelo", "given": "Angela", "sequence": "additional" }, { "affiliation": [ { "name": "Velleja Research S.r.l. Milan Italy" } ], "family": "Di Pierro", "given": "Francesco", "sequence": "additional" } ], "container-title": "Phytotherapy Research", "container-title-short": "Phytotherapy Research", "content-domain": { "crossmark-restriction": true, "domain": [ "onlinelibrary.wiley.com" ] }, "created": { "date-parts": [ [ 2020, 10, 9 ] ], "date-time": "2020-10-09T12:10:04Z", "timestamp": 1602245404000 }, "deposited": { "date-parts": [ [ 2023, 9, 2 ] ], "date-time": "2023-09-02T03:14:35Z", "timestamp": 1693624475000 }, "indexed": { "date-parts": [ [ 2024, 5, 1 ] ], "date-time": "2024-05-01T07:32:50Z", "timestamp": 1714548770820 }, "is-referenced-by-count": 182, "issue": "3", "issued": { "date-parts": [ [ 2020, 10, 9 ] ] }, "journal-issue": { "issue": "3", "published-print": { "date-parts": [ [ 2021, 3 ] ] } }, "language": "en", "license": [ { "URL": "http://onlinelibrary.wiley.com/termsAndConditions#vor", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2020, 10, 9 ] ], "date-time": "2020-10-09T00:00:00Z", "timestamp": 1602201600000 } } ], "link": [ { "URL": "https://onlinelibrary.wiley.com/doi/pdf/10.1002/ptr.6887", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://onlinelibrary.wiley.com/doi/full-xml/10.1002/ptr.6887", "content-type": "application/xml", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://onlinelibrary.wiley.com/doi/pdf/10.1002/ptr.6887", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "311", "original-title": [], "page": "1230-1236", "prefix": "10.1002", "published": { "date-parts": [ [ 2020, 10, 9 ] ] }, "published-online": { "date-parts": [ [ 2020, 10, 9 ] ] }, "published-print": { "date-parts": [ [ 2021, 3 ] ] }, "publisher": "Wiley", "reference": [ { "DOI": "10.2174/1876396001104010189", "doi-asserted-by": "publisher", "key": "e_1_2_13_2_1" }, { "DOI": "10.1039/C5SC02678D", "doi-asserted-by": "publisher", "key": "e_1_2_13_3_1" }, { "DOI": "10.4103/0973-7847.194044", "doi-asserted-by": "publisher", "key": "e_1_2_13_4_1" }, { "DOI": "10.1016/j.ctim.2019.102294", "doi-asserted-by": "publisher", "key": "e_1_2_13_5_1" }, { "DOI": "10.1016/j.tim.2013.05.005", "doi-asserted-by": "publisher", "key": "e_1_2_13_6_1" }, { "DOI": "10.1016/j.antiviral.2011.09.005", "doi-asserted-by": "publisher", "key": "e_1_2_13_7_1" }, { "DOI": "10.1021/acs.jcim.7b00341", "doi-asserted-by": "publisher", "key": "e_1_2_13_8_1" }, { "DOI": "10.1016/S0140-6736(20)30211-7", "doi-asserted-by": "publisher", "key": "e_1_2_13_9_1" }, { "DOI": "10.3390/ijms20122957", "doi-asserted-by": "publisher", "key": "e_1_2_13_10_1" }, { "DOI": "10.1016/j.apjtm.2015.12.002", "doi-asserted-by": "publisher", "key": "e_1_2_13_11_1" }, { "DOI": "10.3390/nu11102288", "doi-asserted-by": "publisher", "key": "e_1_2_13_12_1" }, { "DOI": "10.5582/ddt.2020.01012", "doi-asserted-by": "publisher", "key": "e_1_2_13_13_1" }, { "DOI": "10.1128/AAC.00530-20", "doi-asserted-by": "publisher", "key": "e_1_2_13_14_1" }, { "DOI": "10.1038/nprot.2016.051", "doi-asserted-by": "publisher", "key": "e_1_2_13_15_1" }, { "DOI": "10.1038/s41591-020-0869-5", "doi-asserted-by": "publisher", "key": "e_1_2_13_16_1" }, { "DOI": "10.1016/j.phrs.2010.05.001", "doi-asserted-by": "publisher", "key": "e_1_2_13_17_1" }, { "DOI": "10.1016/S0140-6736(20)30183-5", "doi-asserted-by": "publisher", "key": "e_1_2_13_18_1" }, { "DOI": "10.1016/j.ijid.2020.01.009", "doi-asserted-by": "publisher", "key": "e_1_2_13_19_1" }, { "DOI": "10.1111/cbdd.13604", "doi-asserted-by": "publisher", "key": "e_1_2_13_20_1" }, { "DOI": "10.1080/14756366.2019.1690480", "doi-asserted-by": "publisher", "key": "e_1_2_13_21_1" }, { "article-title": "Potential inhibitor of COVID‐19 main protease (Mpro) from several medicinal plant compounds by molecular docking study", "author": "Khaerunnisa S.", "first-page": "2020030226", "journal-title": "Preprints", "key": "e_1_2_13_22_1", "year": "2020" }, { "DOI": "10.1016/j.autrev.2019.05.001", "doi-asserted-by": "publisher", "key": "e_1_2_13_23_1" }, { "article-title": "Quercetin: A versatile flavonoid", "author": "Lakhanpal P.", "first-page": "22", "journal-title": "International Journal of Medicine", "key": "e_1_2_13_24_1", "volume": "2", "year": "2007" }, { "DOI": "10.7326/M20-0504", "doi-asserted-by": "publisher", "key": "e_1_2_13_25_1" }, { "DOI": "10.1056/NEJMoa2001316", "doi-asserted-by": "publisher", "key": "e_1_2_13_26_1" }, { "DOI": "10.1002/jcc.20186", "doi-asserted-by": "publisher", "key": "e_1_2_13_27_1" }, { "DOI": "10.1016/j.thromres.2010.08.006", "doi-asserted-by": "publisher", "key": "e_1_2_13_28_1" }, { "DOI": "10.1002/jmv.25761", "doi-asserted-by": "publisher", "key": "e_1_2_13_29_1" }, { "DOI": "10.1186/s13020-020-00317-x", "doi-asserted-by": "publisher", "key": "e_1_2_13_30_1" }, { "DOI": "10.1016/j.virusres.2020.197989", "doi-asserted-by": "publisher", "key": "e_1_2_13_31_1" }, { "DOI": "10.2298/VSP1511951M", "doi-asserted-by": "publisher", "key": "e_1_2_13_32_1" }, { "DOI": "10.1007/s10529-011-0845-8", "doi-asserted-by": "publisher", "key": "e_1_2_13_33_1" }, { "DOI": "10.1007/s12272-012-0108-9", "doi-asserted-by": "publisher", "key": "e_1_2_13_34_1" }, { "DOI": "10.1080/14756366.2016.1265519", "doi-asserted-by": "publisher", "key": "e_1_2_13_35_1" }, { "article-title": "Repurposing therapeutics for COVID‐19: Supercomputer‐based docking to the SARS‐CoV‐2 viral spike protein and viral spike protein‐human ACE2 interface", "author": "Smith M.", "journal-title": "ChemRxiv", "key": "e_1_2_13_36_1", "year": "2020" }, { "DOI": "10.1186/1743-422X-8-460", "doi-asserted-by": "publisher", "key": "e_1_2_13_37_1" }, { "DOI": "10.1016/j.phymed.2015.10.018", "doi-asserted-by": "publisher", "key": "e_1_2_13_38_1" }, { "DOI": "10.1021/jm034137m", "doi-asserted-by": "publisher", "key": "e_1_2_13_39_1" }, { "DOI": "10.1056/NEJMc2004973", "doi-asserted-by": "publisher", "key": "e_1_2_13_40_1" }, { "DOI": "10.1007/s00726-006-0403-1", "doi-asserted-by": "publisher", "key": "e_1_2_13_41_1" }, { "DOI": "10.1001/jama.2020.1585", "doi-asserted-by": "publisher", "key": "e_1_2_13_42_1" }, { "key": "e_1_2_13_43_1", "unstructured": "World Health Organization. (2020a).https://www.who.int/news-room/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov)" }, { "key": "e_1_2_13_44_1", "unstructured": "World Health Organization. (2020b).https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-mission-briefing-on-covid-19---26-february-2020" }, { "DOI": "10.1016/j.joim.2020.02.005", "doi-asserted-by": "publisher", "key": "e_1_2_13_45_1" }, { "DOI": "10.1016/j.clim.2020.108393", "doi-asserted-by": "publisher", "key": "e_1_2_13_46_1" }, { "DOI": "10.1093/infdis/jiaa228", "doi-asserted-by": "publisher", "key": "e_1_2_13_47_1" } ], "reference-count": 46, "references-count": 46, "relation": {}, "resource": { "primary": { "URL": "https://onlinelibrary.wiley.com/doi/10.1002/ptr.6887" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [], "subtitle": [], "title": "A role for quercetin in coronavirus disease 2019 (COVID‐19)", "type": "journal-article", "update-policy": "http://dx.doi.org/10.1002/crossmark_policy", "volume": "35" }

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0